Table 2.

Common toxicities seen in REFLECT, IMBrave-150, and HIMALAYA trial

Trial	Most common treatment-related adverse event	Most common grade 3 or 4 treatment related adverse event
REFLECT3	Hypertension (42%), diarrhea (39%), decreased appetite (34%)	Hypertension (23%), decreased weight (8%), increased blood bilirubin (7%)
IMBrave-1506	Hypertension (29.8%), fatigue (20.4%), proteinuria (20.1%)	Hypertension (15.2%), aspartate aminotransferase increase (7.0%), alanine aminotransferase increase (3.6%)
HIMALAYA8	Diarrhea/colitis (26.5%), pruritus (22.9%), rash (22.4%)	Lipase increase (6.2%), aspartate aminotransferase increase (5.2%), diarrhea/colitis (4.4%)